Compass Pathways reports a Q2 loss of $17.5 million and announces raising $154.8 million in a new financing in May.
Compass Pathways reports a Q2 loss of $17.5 million and announces raising $154.8 million in a new financing in May.
MINDCURE announces that renowned human rights activist, Jerry White, has joined the company as an advisor. Winner of the Nobel Peace Prize, White will help MINDCURE revolutionize mental health.
Atai Life Sciences announces the launch of a new intranasal drug delivery system, InnarisBio, based on sol-gel technology.
MindMed is preparing to commence a Phase I clinical trial on the safety/tolerance of intravenous DMT.
Cybin's new financing is priced at CAD$3.40. The Company intends to issue 8.8 million new units for total proceeds of CAD$30 million.
Cybin Inc is seeking to raise capital with an overnight offering of common shares. Pricing and size of the offering to be determined.
Field Trip Health to commence trading on the NASDAQ on July 27th under the symbol "FTRP".
MINDCURE's proprietary ibogaine manufacturing has reached the second stage of development: assessing the quality of its synthetic ibogaine.
Red Light Holland reports an updated position in cash and cash equivalents of roughly CAD$30 million following its merger with Creso Pharma.
Levitee Labs announces definitive agreements to acquire 3 specialized pharmacies, a "leading telehealth provider", and 5 addiction clinics.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now